Company Encyclopedia
View More
name
Shouxiangu
603896.SH
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. researches, develops, and sells Chinese medicine products. It offers ganoderma lucidum spore powder, dendrobium officinale and ganoderma lucidum extract, dendrobium officinale granules, saffron extract, crocus sativus, and other health products. Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
255.10 B
603896.SHMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
C
Personal Care ProductsIndustry
Industry Ranking21/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.00%C
    • Profit Margin21.21%A
    • Gross Margin75.06%A
  • Growth ScoreD
    • Revenue YoY-10.85%D
    • Net Profit YoY-40.70%D
    • Total Assets YoY3.28%C
    • Net Assets YoY3.62%C
  • Cash ScoreD
    • Cash Flow Margin471.47%C
    • OCF YoY-10.85%D
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreB
    • Gearing Ratio26.69%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shouxiangu released its performance for the first three quarters, with a net profit attributable to the parent company of 76.34 million yuan, a year-on-year decrease of 33.47%

    According to the Zhitong Finance APP, Shouxiangu disclosed its third-quarter report for 2025. The company achieved revenue of 430 million yuan in the first three quarters, a year-on-year decrease of 10.23%; net profit attributable to the parent company was 76.34 million yuan, a year-on-year decrease of 33.47%; net profit excluding non-recurring gains and losses was 42.29 million yuan, a year-on-year decrease of 54.48%; basic earnings per share were 0.39 yuan

    Zhitong·
    SH
    603896
    +0.20%
    Zhitong·
    SH
    603896
    +0.20%

    Shouxiangu: Subsidiary "Shouxiangu Brand Ganoderma Spore Oil Soft Capsules" product completes re-registration as a domestic health food

    Shouxiangu announced that its wholly-owned subsidiary Jinhua Shouxiangu Pharmaceutical Co., Ltd. has completed the re-registration of the "Shouxiangu Brand Ganoderma Spore Oil Soft Capsules" product as a domestic health food and has obtained the domestic health food registration certificate issued by the State Administration for Market Regulation. This product has been evaluated through animal experiments and is found to have health benefits that help enhance immunity, with registration number Guo Shi Jian Zhu G20200107, valid until August 25, 2030

    Zhitong·
    SH
    603896
    +0.20%
    Zhitong·
    SH
    603896
    +0.20%

    Shouxiangu: 2025 Shareholder Return Program Launch

    Shouxiangu announced that the 2025 shareholder return event will be held from September 23 to October 22, 2025. Eligible shareholders can purchase the company's products at discounted prices, including Shouxiangu Xianzhi No. 3 broken-wall reishi spore powder tablets, Shouxiangu Xianzhi No. 3 broken-wall reishi spore powder, and Shouxiangu sugar-free iron skin maple granules. Individual shareholders need to participate by scanning the "Shareholder Return Event" QR code via WeChat, while corporate shareholders must submit identification information and undergo verification. The event does not constitute a profit distribution, and the company has the final interpretation rights for the event

    Zhitong·
    SH
    603896
    +0.20%
    Zhitong·
    SH
    603896
    +0.20%

    Shouxiangu: Net profit of 65.5586 million yuan in the first half of 2025, a year-on-year decrease of 33.99%

    Shouxiangu announced that its operating revenue in the first half of 2025 was 300 million yuan, a year-on-year decrease of 16.51%. The net profit was 65.5586 million yuan, a year-on-year decrease of 33.99%

    Zhitong·
    SH
    603896
    +0.20%
    Zhitong·
    SH
    603896
    +0.20%

    Shouxiangu: Two products have completed the domestic health food filing

    Shouxiangu announced that its wholly-owned subsidiary Jinhua Shouxiangu Pharmaceutical Co., Ltd. has completed the domestic health food filing for two products: "Shouxianyun® Broken Wall Ganoderma Spore Powder Tablets" and "Shouxianhong® Broken Wall Ganoderma Spore Powder Tablets," and has obtained the filing certificate from the Zhejiang Provincial Market Supervision Administration. This filing will help enrich the company's product line, enhance its competitiveness in the health food sector, and align with the company's strategic planning in the big health industry

    Zhitong·
    SH
    603896
    +0.20%
    Zhitong·
    SH
    603896
    +0.20%
    © 2025 Longbridge｜Disclaimer